For This Small Bio, a Heap of Events in the Second HalfÂ
Research - This small biotech company has three trials reading out in the second half of this year. First up, a phase 3 pivotal sometime this quarter.
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Some Relief for Investors: Zogenix Says New Painkiller as Early as 2015
Insights - Shares of biopharmaceutical company Zogenix, Inc. (ZGNX) are up 16% in trading on Wednesday after the company announced that a new, abuse-deterrent formulation of Zohydro … Continue Reading
Read now
Why Agenus’ Rally on Brain Cancer Results May Be Short-Lived
Insights - Agenus (AGEN) reported on Tuesday updated results from an open-label, single-arm phase 2 study of Prophage, the company’s cancer vaccine, in glioblastoma multiforme. Patients treated with Prophage plus standard of care … Continue Reading
Read now
No Surprise Here, Synageva is On Its Way to the FDA
Insights - Synageva BioPharma (GEVA) announced Monday after the close that the phase 3 ARISE trial of lead drug candidate sebelipase alfa successfully met its primary endpoint, and the company will … Continue Reading
Read now
Retrophin Plummets Before All-Day Rally on Early Drug Results
Insights - Retrophin (RTRX) dropped on Friday before rallying through the day on early results for RE-024. Here's why.
Read now
Flamel Adds Another ‘Approved Unapproved’ Product To its Portfolio
Insights - Flamel Technologies (FLML) announced on Monday that the FDA has approved VAZCULEP (phenylephrine hydrochloride), the company’s alpha-1 adrenergic receptor agonist for the treatment of hypotension resulting … Continue Reading
Read now
Inhaled Insulin, Breakthrough in Cystic Fibrosis and so Much More
Recap - The announcement came two weeks ahead of schedule, and Afrezza is now approved to improve glycemic control in adults with diabetes mellitus. Afrezza’s label includes a Black Box Warning … Continue Reading
Read now